Veza, the Data Security Platform Built on the Power of Authorization, Announces Partnership with Google Cloud
19.7.2022 16:00:00 EEST | Business Wire | Press release
Veza, the data security platform built on the power of authorization, announces today that the company has entered a partnership with Google Cloud, including product integration that enables Google Cloud customers to harness the capabilities of Veza’s data security platform across their multi-cloud ecosystem.
Veza, which recently launched in April 2022 after two years of building in stealth, makes it easy to understand, manage, and control who can and should take what action on what data. With this new integration, Google Cloud customers can now directly access the capabilities of Veza’s authorization-based data security platform integrated with Google Cloud Policy Analyzer to identify, manage, and control external identities and service accounts to Google Cloud services (Looker, BigQuery, and more). This partnership furthers the relationship between Google and Veza, which began in 2021 when GV led the Series B investment in Veza and GV Partner Karim Faris joined Veza Board of Directors.
“The cloud is quickly becoming the primary footprint for organizations. By prioritizing and investing in security, Google Cloud has earned a differentiated position in the market,” said Tarun Thakur, Co-founder and CEO, Veza. “The initial product integration between Veza and Google Cloud, publicly demonstrated at the Google Cloud Security Summit in May this year, is a powerful example of how intelligence from Veza’s Authorization Graph can bolster the data security of Google Cloud customers. It shows how identity-to-data relationship insights from the Veza platform can be pulled directly into the Google Cloud Policy Analyzer, allowing customers to secure both Google Cloud data (Looker, BigQuery, Google Storage Buckets, etc.) to which multi-cloud identities (AD, Azure AD, Okta, etc.) have permissions and multi-cloud data (AWS, Snowflake, etc.) that is being accessed by Google Cloud identities.”
“Securing cloud environments and data from cybercrime and threats is a key priority of organizations across the globe,” said Sunil Potti, General Manager and Vice President, Cloud Security, Google Cloud. “With Veza’s platform now available alongside Google Cloud’s secure and global infrastructure, customers will be able to quickly deploy the solutions they need to better understand, control, and securely take action on their data across their multi-cloud environments.”
Veza’s data security platform aggregates identity information from humans, service accounts, and cloud IAM entities, and authorization data from apps and data systems, giving organizations a centralized, SaaS-based control plane to visualize, manage, and control data access controls through Veza’s Authorization Graph. Veza integrates with cloud identity providers, SaaS and custom apps, and data systems, and translates system-specific entitlements and permissions into a common, human-understandable business language, visualized in the platform as effective permissions. The platform brings a novel approach to data security by enabling organizations to address key data security use cases across access reviews and certifications for SaaS apps and data systems, privileged access management to data and apps, data lake security and governance, management of cloud entitlements, and much more. It delivers prioritized insights, provides access workflows, and actionable recommendations for remediation of over-privileged accounts, enabling security and IT teams to correct anomalies and right-size their organization’s permissions to protect against ransomware and other data breaches.
As organizations continue to adapt to the evolving demands of hybrid remote and in-office work, multi-cloud and hybrid-cloud environments — those with multiple providers of disparate data, app, compute, and infrastructure systems — are becoming the norm. According to the Flexera 2022 State of the Cloud Report, 89% of companies surveyed are multi-cloud, with only 2% operating in single private clouds and 9% in single public clouds. This trend is leading to a distributed web of data, relationships, and access points that are changing and difficult to track and secure.
Veza and Google Cloud already have a number of joint customers deployed across the industries of SaaS software, marketing technology, and media, including Vox Media.
“To support Vox Media’s growth and increasing M&A activity without compromising security, we need to ensure that across all of our brands, the right users have access only to the data they need access to, and that we have full visibility over what they can do with that data,” says Ateeb Ahmad , Senior Director, IT Infrastructure, Vox Media. With Veza and Google Cloud working together, we’ve been able to seamlessly manage access controls over our data for our largest merger to date, and tightly scope identity-to-data permissions even as our footprint with Google Cloud and other technologies grows.”
“The greatest gifts of the multi-cloud and the generational architectural shift of the modern data systems are also its greatest risks: securing data, scalability, flexibility, and seamless collaboration,” says Thakur. “When organizations enable workers to reach from one cloud to another to leverage data across their entire multi-cloud ecosystem, they foster growth, enable more intelligence, and promote agility. However, such apps and data systems are also more porous and are at increased risk of cybercrime and ransomware. We purpose-built Veza’s Core Authorization Platform for the multi-cloud so that organizations can implement strong access governance policies - Veza continuously evaluates these policies and enables both automated workflows for access reviews, automated access removal for toxic and stale combinations, and facilitates access grant and request for any app, data, and service.”
Learn More:
Google Cloud Security Summit - Best practices for defining and enforcing policies across your Google Cloud environment
Veza for Google Cloud demo
Veza for Google Cloud
Veza Free Trial - sign up here
About Veza
Veza is the data security platform built on the power of authorization. Our platform is purpose-built for hybrid multi-cloud environments to help you use and share your data safely. Veza makes it easy to understand, manage, and control who can and should take what action on what data. We organize authorization metadata across identity providers, data systems, cloud service providers, and SaaS applications — all to address the toughest data security challenges of the modern era. Founded in 2020, the company is funded by top-tier investors including Accel, Bain Capital, Ballistic Ventures, Blackstone, GV, Norwest Venture Partners, and True Ventures. To learn more, please visit us at veza.com. You can follow us on LinkedIn or on Twitter @vezainc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005324/en/
Contact information
Aircover PR
veza@aircoverpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release
Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release
Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release
Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
